Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 7/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 0.54 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.54 |
| ▸ | HTR5A known ✓ | P47898 | 2/20 | 0.54 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.54 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.54 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.54 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.54 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.54 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.54 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.54 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.50 |
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.48 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23270836 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1LMNAHPGDPMP22 | |
| Hydrochloric Acid SCHEMBL31094011 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1LMNAHPGDPMP22 | |
| Hydrochloric Acid SCHEMBL29433207 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1LMNAHPGDPMP22 | |
| SCHEMBL294010 | 0.98 | HTR1A (0.56) | KDM4EALDH1A1LMNAHPGDPMP22 | |
| SCHEMBL24719283 | 0.92 | HTR1A (0.50) | KDM4EALDH1A1LMNAHPGDPMP22 | |
| SCHEMBL14671117 | 0.86 | DRD2 (0.57) | HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL29433198 | 0.86 | DRD2 (0.57) | HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL16449540 | 0.81 | DRD2 (0.50) | HTR1AHTR2AHTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL16443155 | 0.81 | HTR2C (0.48) | KDM4EALDH1A1LMNAHPGDPMP22 | |
| SCHEMBL19258305 | 0.81 | HTR2C (0.42) | HTR1AHTR2AHTR6HTR5AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118858483-A | Method for detecting related substances of epinastine intermediate 4-piperazinyl benzothiophene hydrochloride | 万特制药(海南)有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-115894434-B | Preparation method of 4-piperazinyl benzothiophene hydrochloride | 山东厚德精诚药业有限公司 | 2024-10-08 | — | — | CN | claimed |
| CN-117946066-A | Synthesis method of bripiprazole intermediate | 江苏宇锐医药科技有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117645602-A | Impurity removal method of bripiprazole intermediate and preparation method of bripiprazole | 黑龙江珍宝岛药业股份有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-115677655-B | Synthesis method of epinastine intermediate | 湖南省湘中制药有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-114166960-B | Method for detecting substances related to epipiprazole | 西安远大科创医药科技有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-116425716-A | Preparation method of epinastine intermediate | 南京艾德凯腾生物医药有限责任公司 | 2023-07-14 | — | — | CN | claimed |
| CN-115894435-A | Synthesis method of 1- (benzo [ b ] thiophene-4-yl) piperazine hydrochloride | 山东厚德精诚药业有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115894434-A | Preparation method of 4-piperazinyl benzothiophene hydrochloride | 山东厚德精诚药业有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115677655-A | Synthesis method of brexpiprazole intermediate | 湖南省湘中制药有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-104844585-B | Method for preparing brexpiprazole | 重庆医药工业研究院有限责任公司 | 2021-05-11 | — | — | CN | claimed |
| CN-109970705-B | Method for preparing brexpiprazole intermediate and brexpiprazole by using cheap metal copper | 浙江工业大学 | 2021-02-09 | — | — | CN | claimed |
| US-10464931-B2 | Process for the preparation of Quinolin-2(1H)-one derivatives | HONOUR (R&D) (IN) | 2019-11-05 | — | — | US | claimed |
| US-10358440-B2 | Process for the preparation of brexpiprazole and intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2019-07-23 | — | — | US | claimed |
| CN-109970705-A | A method of it is standby according to piperazine azoles intermediate and according to a piperazine azoles using cheap metal copper | 浙江工业大学 | 2019-07-05 | — | — | CN | claimed |
| US-20190177309-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2019-06-13 | — | — | US | claimed |
| US-20190010145-A1 | PROCESS FOR THE PREPARATION OF QUINOLIN-2(IH)-ONE DERIVATIVES | HONOUR (R&D) (IN) | 2019-01-10 | — | — | US | claimed |
| EP-3397636-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE-2(1H)-ONE DERIVATIVES | Honour (R&D) (IN) | 2018-11-07 | — | — | EP | claimed |
| US-20170320862-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2017-11-09 | — | — | US | claimed |
| WO-2017115287-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE-2(1H)-ONE DERIVATIVES | HONOUR (R&D) (IN) | 2017-07-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177309-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND INTERMEDIATES THEREOF | CYP4Z1, CYP4X1, CYP4B1 | HTR1A 251/4885HTR2A 256/4885HTR6 739/4885 |
| US-10358440-B2 | Process for the preparation of brexpiprazole and intermediates thereof | CYP4Z1, CYP4X1, CYP4B1 | HTR1A 251/4885HTR2A 256/4885HTR6 739/4885 |
| US-20170320862-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND INTERMEDIATES THEREOF | CYP4Z1, CYP4X1, CYP4B1 | HTR1A 251/4885HTR2A 256/4885HTR6 739/4885 |
| US-10464931-B2 | Process for the preparation of Quinolin-2(1H)-one derivatives | UGT1A1, CYP1A2, CYP1A1 | HTR1A 184/4885HTR2A 287/4885HTR6 830/4885 |
| US-20190010145-A1 | PROCESS FOR THE PREPARATION OF QUINOLIN-2(IH)-ONE DERIVATIVES | UGT1A1, CYP1A2, SDHA | HTR1A 96/4885HTR2A 82/4885HTR6 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.